The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
BUSINESS
2 Ono Employees Admits Bribery Charges over Onoact Prescriptions
Two employees of Ono Pharmaceutical on May 14 admitted the charges of bribery they face for giving 2 million yen to a university hospital professor in the name of scholarship donations (shogaku-kifu) to boost prescriptions of the company’s anti-arrhythmic drug…
To read the full story
Related Article
- Maker FTC Issues “Warning” to Ono over Onoact Bribery Case
December 16, 2021
- Probe Panel Urges Ono to Establish Foundation to Handle Scholarship Donations after Bribery Case
August 16, 2021
- Guilty Ruling for Ono Employees Now Final and Binding: Onoact Case
July 15, 2021
- 2 Ono Employees Found Guilty for Onoact Bribery Charges; Scholarship Donation in Spotlight
June 30, 2021
- Jail Terms Sought for 2 Ono Employees over Onoact-Tied Bribery Charges
June 1, 2021
- Ono President Apologizes to JPMA After 2 Employees Are Indicted for Bribery
February 22, 2021
- Ono Sets Up Investigation Panel on Bribery Issue
February 19, 2021
- Ono Apologizes over Arrest of 2 Employees on Bribery Allegations
January 29, 2021
BUSINESS
- iPark Institute to Launch AI-Based Platform to Link Investors with Startups
January 16, 2026
- Acromegaly Drug Palsonify Meets Primary Endpoint in Japan PII/PIII Trial
January 16, 2026
- Tanabe’s EPP/XLP Drug Hits Main Goals in PIII, Weighs Launch Strategy
January 16, 2026
- Forxiga Generics Reach 11% Share in First Month: Intage
January 16, 2026
- Takeda to Halt Sales of Cell Therapy Alofisel in Japan
January 15, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…